Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that it has entered into a securities purchase agreement for a private placement (the "Private Placement") led by funds affiliated with BVF Partners L.P. ("BVF").

The Private Placement is expected to close on or about April 2, 2026, subject to customary closing conditions. Pursuant to the Private Placement, the Company agreed to issue and sell an aggregate of 7,827,789 units (the "Units") at a purchase price of $1.2775 per Unit. Each Unit consists of (i) one ordinary share of Entera (or, in lieu thereof, one pre-funded warrant) and (ii) one five-year warrant to purchase one and a half ordinary shares at an exercise price of $1.24 per share, representing a 11.7% premium to the Company's closing price on March 31, 2026.

Gross proceeds to the Company from the Private Placement are expected to be approximately $10.0 million, before deducting offering expenses, subject to satisfaction of customary closing conditions. If all warrants issued in the Private Placement are exercised for cash, the Company could receive additional proceeds of approximately $14.5 million, resulting in total potential proceeds of approximately $24.5 million.

The warrants to be issued in the Private Placement will become exercisable six months following the closing date, and will expire five years following the date of issuance. The warrants will be exercisable only for cash, except in certain circumstances. The pre-funded warrants to be issued in the Private Placement will have an exercise price of NIS 0.0000769 per share, will be immediately exercisable upon issuance and will not expire.

The Company intends to use the net proceeds from the Private Placement together with existing cash and cash equivalents to support activities related to initiation of the phase 3 registrational study of EB613 in postmenopausal women with osteoporosis and for general working capital and corporate purposes.

The securities described above are being offered in a private placement pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.